[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
KI Inquiry
- To: RADSAFE@ROMULUS.ehs.uiuc.edu
- Subject: KI Inquiry
- From: "Thompson, Donald L. 827-0012" <DLT@FDADR.CDRH.FDA.GOV>
- Date: Fri, 18 Oct 1996 09:52:11 EST
- A1-Type: MAIL
- Alternate-Recipient: prohibited
- Hop-Count: 0
- Importance: normal
- Mr-Received: by mta CVAX3; Relayed; Fri, 18 Oct 1996 10:06:33 -0500 (EST)
- Posting-Date: Fri, 18 Oct 1996 10:06:00 EST
- Priority: normal
- Ua-Content-Id: D282ZWNNEG8Y8
- X400-Mts-Identifier: [;33600181016991/969677@FDADR]
Response to: "Without knowing the doses, it is unclear to me that the KI would
have been needed in Poland."
Based on notes taken during a presentation at HIH by Prof. Janusz Nauman, who
directed the program of KI distribution in Poland, the intervention dose for
adults was 50 rem. In the Warsaw area, the doses only reached one-quarter of
this, but hot spots in other areas reached two to three times the intervention
level.
Side effects occurred in 4.5% of recipients, somewhat lower in children age
10-16 than in other age groups.
No - mumps or swollen parotid glands
Yes- vomiting and skin rashes (mild and transient)
Yes- lower incidences of headache, stomach ache, diarrhea, shortness of
breath
Don Thompson DLT@FDADR.CDRH.FDA.GOV